AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1734249 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered through a nasogastric tube
Number of subjects: 445
Study 1734249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nonabsorbable antibiotics
Number of subjects: 445
Study 1734249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 6094447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefotaxime, 1 g preoperatively
Number of subjects: 136
Study 6094447 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of cefoxitin, 2 g preoperatively followed by 2 g every 6 h for no more than 24 h
Number of subjects: 136
Study 31429950 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-balance ultrafiltration (Z-BUF) of the priming blood with 0.45% saline
Number of subjects: 60
Study 31429950 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Z-BUF)
Number of subjects: 60
Study 31735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Management (CM) with telemonitoring for 12 months
Number of subjects: 59
Study 31735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Management (CM)
Number of subjects: 59
Study 31735786 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 59
Study 31735786 — intervention group
Group type: COMPARATOR
Intervention: Self-Management (SM)
Number of subjects: 59
Study 29037617 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Program (STP) using rubber band exercises, 18 sessions
Number of subjects: 25
Study 29037617 — intervention group
Group type: COMPARATOR
Intervention: Control group (D control)
Number of subjects: 25
Study 29037617 — intervention group
Group type: COMPARATOR
Intervention: Control group (ND control)
Number of subjects: 25
Study 26294416 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mini-implants
Number of subjects: 120
Study 26294416 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mini-implants
Number of subjects: 120
Study 26294416 — intervention group
Group type: COMPARATOR
Intervention: 2 standard implants
Number of subjects: 120
Study 23186610 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Fun program
Number of subjects: 511
Study 21922233 — intervention group
Group type: EXPERIMENTAL
Intervention: IEGM-based optimization
Number of subjects: 48
Study 21922233 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography optimization
Number of subjects: 48
Study 19160729 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17881957 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NIHSS scores
Number of subjects: 1000
Study 17881957 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS items (level of consciousness, dysarthria, visual fields, worst motor score for the arms)
Number of subjects: 1000
Study 14748814 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 18
Study 14748814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48‐6791
Number of subjects: 18
Study 11305828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg lidocaine plus 10 microg sufentanil (Group LS)
Number of subjects: 13
Study 11305828 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 20 microg sufentanil (Group S)
Number of subjects: 13
Study 9383925 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (15 minutes a day for 30 days)
Number of subjects: 0
Study 9383925 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy (control group)
Number of subjects: 0
Study 8195735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clotrimazole solution
Number of subjects: 117
Study 8195735 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Melaleuca alternifolia (tea tree) oil
Number of subjects: 117
Study 3661173 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (EG)
Number of subjects: 104
Study 3661173 — intervention group
Group type: COMPARATOR
Intervention: Late discharge (CG)
Number of subjects: 104
Study 31929466 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling-focused ISTDP (FF-ISTDP)
Number of subjects: 41
Study 31929466 — intervention group
Group type: EXPERIMENTAL
Intervention: Defense-focused ISTDP (DF-ISTDP)
Number of subjects: 41
Study 31929466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 30078167 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil + methadone (MET) (0.1 mg/kg IV over 15 min)
Number of subjects: 60
Study 30078167 — intervention group
Group type: COMPARATOR
Intervention: remifentanil (REMI)
Number of subjects: 60
Study 30078167 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil + magnesium (MAG) (50 mg/kg bolus over 30 min followed by 10 mg/kg/h)
Number of subjects: 60
Study 30078167 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil + methadone (MET)
Number of subjects: 60
Study 30078167 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil + magnesium (MAG)
Number of subjects: 60
Study 27528533 — intervention group
Group type: EXPERIMENTAL
Intervention: Three evidence-based programs with shared theories and intervention elements
Number of subjects: 0
Study 26643501 — intervention group
Group type: EXPERIMENTAL
Intervention: CRUSADE score >40 with 24-month dual antiplatelet therapy
Number of subjects: 1946
Study 26643501 — intervention group
Group type: EXPERIMENTAL
Intervention: CRUSADE score ≤40 with 24-month dual antiplatelet therapy
Number of subjects: 1946
Study 26643501 — intervention group
Group type: COMPARATOR
Intervention: CRUSADE score >40 with 6-month dual antiplatelet therapy
Number of subjects: 1946
Study 26643501 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUITY score
Number of subjects: 1946
Study 26643501 — intervention group
Group type: COMPARATOR
Intervention: HAS-BLED score
Number of subjects: 1946
Study 26643501 — intervention group
Group type: EXPERIMENTAL
Intervention: CRUSADE score improvement
Number of subjects: 1946
Study 23554277 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 103
Study 23554277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 103
Study 20958276 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 54
Study 20958276 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 54
Study 20958276 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 54
Study 18831886 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg/day) and calcium (900 mg/day)
Number of subjects: 33
Study 18831886 — intervention group
Group type: COMPARATOR
Intervention: Calcium (900 mg/day) alone
Number of subjects: 33
Study 16487622 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression with Basiliximab and cyclosporine with prednisone (St Group)
Number of subjects: 198
Study 16487622 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppression with Basiliximab and cyclosporine without prednisone (NoSt Group)
Number of subjects: 198
Study 12859610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-directional bicycle pedal
Number of subjects: 19
Study 12859610 — intervention group
Group type: COMPARATOR
Intervention: Traditional uni‐directional bicycle pedal (Control)
Number of subjects: 19
Study 11268446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HCFU, 300 mg daily for 52 weeks starting 2 weeks after surgery
Number of subjects: 316
Study 11268446 — intervention group
Group type: COMPARATOR
Intervention: 5-FU intravenous injection, 333 mg/m2 body surface area/24 hours continuously for 72 hours starting on postoperative day 0 and 6
Number of subjects: 316
Study 9069156 — intervention group
Group type: EXPERIMENTAL
Intervention: bb genotype
Number of subjects: 90
Study 9069156 — intervention group
Group type: EXPERIMENTAL
Intervention: BB genotype
Number of subjects: 90
Study 9069156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bb genotype
Number of subjects: 90
Study 9069156 — intervention group
Group type: COMPARATOR
Intervention: Osteoporosis patients
Number of subjects: 90
Study 9069156 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 90
Study 8256242 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (1 mg)
Number of subjects: 9
Study 8256242 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg)
Number of subjects: 9
Study 8256242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 9
Study 3946550 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity groups (drawing and making collages)
Number of subjects: 22
Study 3946550 — intervention group
Group type: COMPARATOR
Intervention: Discussion groups (describing positive life events)
Number of subjects: 22
Study 29653535 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM)
Number of subjects: 300
Study 29653535 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 300
Study 27219886 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplements containing 3 probiotic bacteria (Lactobacillus acidophilus 2×10^9, Lactobacillus casei 2×10^9, Bifidobacterium bifidum 2×10^9 CFU/g) plus 800 mg inulin
Number of subjects: 60
Study 26133741 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low‐molecular‐weight heparin calcium (n=44)
Number of subjects: 89
Study 26133741 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n=45)
Number of subjects: 89
Study 26133741 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low‐molecular‐weight heparin calcium
Number of subjects: 89
Study 26133741 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 89
Study 26133741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 23247052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological weight loss treatment
Number of subjects: 119
Study 21982660 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACE-I) with quinapril
Number of subjects: 78
Study 21982660 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 78
Study 18957616 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with BQ-123 (type A endothelin receptor antagonist)
Number of subjects: 0
Study 18957616 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 0
Study 18957616 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with BQ-123
Number of subjects: 0
Study 18957616 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (higher dosing in obese subjects)
Number of subjects: 0
Study 16565854 — intervention group
Group type: COMPARATOR
Intervention: Complete inflow occlusion (CIO)
Number of subjects: 118
Study 16565854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique of hepatic vascular exclusion (MTHVE)
Number of subjects: 118
Study 16565854 — intervention group
Group type: COMPARATOR
Intervention: CIO
Number of subjects: 118
Study 16565854 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHVE
Number of subjects: 118
Study 12496951 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg, i.v.)
Number of subjects: 0
Study 12496951 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 10815372 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced allocation
Number of subjects: 0
Study 10815372 — intervention group
Group type: COMPARATOR
Intervention: Simple randomization
Number of subjects: 0
Study 8640056 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked donor breast milk
Number of subjects: 54
Study 8640056 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 54
Study 1616160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of alfentanil (lockout interval of 3 min)
Number of subjects: 80
Study 1616160 — intervention group
Group type: COMPARATOR
Intervention: Physician-controlled administration of alfentanil
Number of subjects: 80
Study 1616160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of alfentanil
Number of subjects: 80
Study 6511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride 0.01%
Number of subjects: 0
Study 6511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.01%
Number of subjects: 0
Study 6511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride 0.02%
Number of subjects: 0
Study 6511230 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (control)
Number of subjects: 0
Study 6511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.01% (in humans)
Number of subjects: 0
Study 6511230 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride 0.01% (in humans)
Number of subjects: 0
Study 31496668 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected exercise (SSE) intensity session
Number of subjects: 20
Study 31496668 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study 29169572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy with opportunistic bilateral salpingectomy
Number of subjects: 104
Study 29169572 — intervention group
Group type: COMPARATOR
Intervention: Standard hysterectomy
Number of subjects: 104
Study 26686380 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 9
Study 24687921 — intervention group
Group type: EXPERIMENTAL
Intervention: onartuzumab plus erlotinib (O+E)
Number of subjects: 0
Study 24687921 — intervention group
Group type: COMPARATOR
Intervention: erlotinib (Control)
Number of subjects: 0
Study 23062116 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated bolus advisor (BA)
Number of subjects: 226
Study 23062116 — intervention group
Group type: COMPARATOR
Intervention: Control group (MDI without BA)
Number of subjects: 226
Study 20207925 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) intervention with 2 automated calls over 10 weeks
Number of subjects: 50
Study 20207925 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) intervention
Number of subjects: 50
Study 20207925 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 17386191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 3 cm H20
Number of subjects: 18
Study 17386191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 6 cm H20
Number of subjects: 18
Study 17386191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 3 cm H20 plus PSV 8 cm H20
Number of subjects: 18
Study 17386191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 3 cm H20 plus PSV 12 cm H20
Number of subjects: 18
Study 15808033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of quinine treatment
Number of subjects: 191
Study 15808033 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf-stretching exercises
Number of subjects: 191
Study 15808033 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 191
Study 11991770 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training of the non‐dominant forearm flexors at 80% of maximal voluntary contraction, 3 times per week for 8 weeks
Number of subjects: 17
Study 11991770 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL; N=7)
Number of subjects: 17
Study 11210954 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh length graduated compression stockings
Number of subjects: 5
Study 11210954 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee length graduated compression stockings
Number of subjects: 5
Study 11210954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 5
Study 15374134 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg paroxetine daily for 42 days
Number of subjects: 12
Study 15374134 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine daily for 42 days
Number of subjects: 12
Study 15374134 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 8198851 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention programme involving nose blowing, deep breathing, coughing, and exercise performed daily
Number of subjects: 0
Study 8198851 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2822878 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 2822878 — intervention group
Group type: COMPARATOR
Intervention: Other drugs (not specified)
Number of subjects: 0
Study 2822878 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum effective dosage of ACE inhibitors
Number of subjects: 0
Study 2822878 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation for at least 6 hours
Number of subjects: 0
Study 2822878 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine rest, infusion of angiotensin II, atropine, saline
Number of subjects: 0
Study 30365798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballroom dancing
Number of subjects: 60
Study 30365798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ballroom dancing)
Number of subjects: 60
Study 27314763 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief parent‐delivered treatment for child anxiety
Number of subjects: 60
Study 27314763 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with strategies specifically targeting parental tolerance of their child's negative emotions
Number of subjects: 60
Study 25714521 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping or coiling treatment (specifics on dosage and duration not available)
Number of subjects: 471
Study 25714521 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive a VPS at discharge
Number of subjects: 471
Study 23225796 — intervention group
Group type: COMPARATOR
Intervention: Increased dose of clopidogrel (aspirin 100 mg + clopidogrel 150 mg daily)
Number of subjects: 73
Study 23225796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (aspirin 100 mg + clopidogrel 75 mg + cilostazol 100 mg bid daily)
Number of subjects: 73
Study 23225796 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover study after hyporesponsiveness
Number of subjects: 73
Study 19906658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg bimonthly)
Number of subjects: 100
Study 19906658 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulphate (dosage not specified)
Number of subjects: 100
Study 18221460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (0.25 mg twice daily for 6 weeks, then half dose for another 6 weeks)
Number of subjects: 31
Study 18221460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (0.25 mg twice daily for 6 weeks, then half dose for another 6 weeks)
Number of subjects: 31
Study 16011907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's bent leg raise (BLR) technique, n=12
Number of subjects: 24
Study 16011907 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, n=12
Number of subjects: 24
Study 12798523 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus Azithromycin
Number of subjects: 597
Study 12798523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study 11970744 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg once daily (n=366)
Number of subjects: 769
Study 11970744 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 40 mg four times daily (n=403)
Number of subjects: 769
Study 8880945 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 60
Study 8880945 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 60
Study 8880945 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 1521670 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg buflomedil given orally twice daily for 90 days
Number of subjects: 73
Study 1521670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31542243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily for a maximum of 52 weeks)
Number of subjects: 69
Study 31542243 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 69
Study 31542243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 69
Study 29972120 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension exercise training in addition to routine rehabilitation training
Number of subjects: 97
Study 29972120 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation training (Control)
Number of subjects: 97
Study 26182441 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4 mg/kg
Number of subjects: 12
Study 26182441 — intervention group
Group type: COMPARATOR
Intervention: Dextrose placebo (PLA)
Number of subjects: 12
Study 24284383 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stenting
Number of subjects: 15
Study 22200399 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling by physical activity coaches
Number of subjects: 226
Study 22200399 — intervention group
Group type: COMPARATOR
Intervention: Control group physician advice to exercise
Number of subjects: 226
Study 20692031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (2 mL, three oral doses at 6, 10, and 14 weeks of age)
Number of subjects: 2036
Study 20692031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three oral doses)
Number of subjects: 2036
Study 20692031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 2036
Study 20692031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2036
Study 17557893 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcomers criticizing their workplace (Experiment 1)
Number of subjects: 411
Study 17557893 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcomers criticizing their profession (Experiment 2)
Number of subjects: 411